Print this Article
RSSBusiness Wire
On a red letter day for Emerging Enterprise Solutions Inc. (NASDAQ: EESI), EESI is pleased to announce its intention to pursue a corporate name change to AMCSI and symbol change to AMCS.
Additionally, subsidiary Elite Ceuticals will meet its December 2004 product release schedule and just moved closer to its goal of infomercials with FDA approval of 17 of the 18 health, wellness and other anti-aging products for both men and women scheduled for December 2004 release. The 18th product, Alpha Lipoic Acid, is considered a natural product in the U.S. and does not require FDA approval.
Alpha Lipoic Acid occurs naturally in the body but diminishes with age. Taking Alpha Lipoic Acid is considered by many doctors and medical professionals to reduce the effects caused by free radicals normally not a problem for the young, thereby lessening the effects of aging.
"Elite Ceuticals is skin care for the 21st century -- promoting Eternal Youth to Fashionable Professionals."
Elite Ceuticals intends to market one or more of its new products through infomercials. Industry reports indicate that a product that is well received through this medium may do in excess of $100,000,000 per infomercial run. Elite Ceuticals offers excellent products for men and women, and is planning to come out with a children's line of products very soon.
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the company will be successful in addressing such risks and uncertainties and the company assumes no duty to update any forward-looking statements based upon actual results.